CA2150946A1 - Treatment of dermatological malignancies with biologically active peptides - Google Patents

Treatment of dermatological malignancies with biologically active peptides

Info

Publication number
CA2150946A1
CA2150946A1 CA002150946A CA2150946A CA2150946A1 CA 2150946 A1 CA2150946 A1 CA 2150946A1 CA 002150946 A CA002150946 A CA 002150946A CA 2150946 A CA2150946 A CA 2150946A CA 2150946 A1 CA2150946 A1 CA 2150946A1
Authority
CA
Canada
Prior art keywords
peptide
amino acid
lys
seq
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002150946A
Other languages
English (en)
French (fr)
Inventor
Leonard S. Jacob
W. Lee Maloy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Magainin Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2150946A1 publication Critical patent/CA2150946A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002150946A 1992-12-03 1993-12-03 Treatment of dermatological malignancies with biologically active peptides Abandoned CA2150946A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98495792A 1992-12-03 1992-12-03
US984,957 1992-12-03

Publications (1)

Publication Number Publication Date
CA2150946A1 true CA2150946A1 (en) 1994-06-09

Family

ID=25531059

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002150946A Abandoned CA2150946A1 (en) 1992-12-03 1993-12-03 Treatment of dermatological malignancies with biologically active peptides

Country Status (5)

Country Link
EP (1) EP0671939A1 (ja)
JP (1) JPH08507749A (ja)
AU (1) AU5743194A (ja)
CA (1) CA2150946A1 (ja)
WO (1) WO1994012206A1 (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9504761D0 (en) * 1995-03-09 1995-04-26 Unilever Plc Amphiphilic peptide and analogs thereof
US6066319A (en) * 1996-04-30 2000-05-23 President And Fellows Of Harvard College Drug delivery using terminal complement components
US8283315B2 (en) 1998-08-28 2012-10-09 Lytix Biopharma As Inhibition of tumour growth
GB9818938D0 (en) 1998-08-28 1998-10-21 Alpharma As Bioactive peptides
US6379903B1 (en) * 1999-10-08 2002-04-30 Sigma-Aldrich Co. Purification of recombinant proteins fused to multiple epitopes
AU2003288507A1 (en) * 2002-12-19 2004-07-14 Yitzchak Hillman Disease treatment via antimicrobial peptide inhibitors
US9044438B2 (en) 2005-06-17 2015-06-02 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
US8202835B2 (en) 2005-06-17 2012-06-19 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
CN102089320B (zh) 2008-01-24 2015-11-25 埃斯佩兰斯医药公司 溶解结构域融合构建体及其制备和使用方法
EP2168592A1 (en) * 2008-09-24 2010-03-31 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Antimicrobial peptides
WO2011137245A2 (en) 2010-04-30 2011-11-03 Esperance Pharmaceuticals, Inc. Lytic-peptide-her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use
KR20210090298A (ko) 2012-10-30 2021-07-19 에스퍼란스 파마슈티컬스, 인코포레이티드 항체/약물 컨쥬게이트 및 이의 사용 방법
US11441118B2 (en) * 2017-11-02 2022-09-13 The Board Of Trustees Of The University Of Illinois Nucleic acid and other compositions and methods for the modulation of cell membranes
CN114133429B (zh) * 2021-11-22 2022-06-24 哈尔滨吉象隆生物技术有限公司 一种杀灭肿瘤细胞的多肽及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810777A (en) * 1987-03-04 1989-03-07 The United States Of America As Represented By The Department Of Health And Human Services Antimicrobial compounds
US4962277A (en) * 1988-12-09 1990-10-09 Scripps Clinic And Research Foundation Deletion analogues of magainin peptides
US5073542A (en) * 1989-06-07 1991-12-17 Magainin Sciences Inc. CPF peptide compositions and their use in inhibiting growth of target cells or a virus

Also Published As

Publication number Publication date
AU5743194A (en) 1994-06-22
WO1994012206A1 (en) 1994-06-09
EP0671939A1 (en) 1995-09-20
JPH08507749A (ja) 1996-08-20

Similar Documents

Publication Publication Date Title
CA2032059C (en) Wound treatment employing biologically active peptides
CA2150946A1 (en) Treatment of dermatological malignancies with biologically active peptides
AU674525B2 (en) Biologically active peptides having N-terminal substitutions
US5635479A (en) Treatment of gynecological malignancies with biologically active peptides
CA2125494A1 (en) Composition and treatment with biologically active peptides and chelating agents
US5217956A (en) Composition and treatment with biologically active peptides and certain anions
US5654274A (en) Biologically active peptides having N-terminal substitutions
EP0590044A4 (en) Composition and treatment with biologically active peptides having c-terminal substitutions
CA2151046A1 (en) Treatment of septic shock with conjugated biologically active peptides
EP0671930A1 (en) Prophylaxis and treatment of adverse oral conditions with biologically active peptides
EP0441832B1 (en) Composition and treatment with biologically active peptides and certain anions
AU693518B2 (en) Ion-channel forming amphiphilic peptides having n-terminal modifications
US6348445B1 (en) Biologically active peptides with reduced toxicity in animals and a method for preparing same
WO1994019369A1 (en) Treatment of cancerous growths with biologically active peptides and protease inhibitors
CA2040510A1 (en) Composition and treatment with biologically active peptides and toxic cations
WO1999003488A2 (en) Biologically active peptides with reduced toxicity in animals and a method for preparing same
WO1991016918A1 (en) Composition and treatment with biologically active peptides and anti-parasitic agents or anti-fungal agents

Legal Events

Date Code Title Description
FZDE Dead